Posts by El Bachir MOURABIT

In June 2024, Blood Science published a pivotal study led by Dr. Hui Wei from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , investigating the prognostic significance of serum albumin levels in patients with acute myeloid leukemia (AML). AML is a highly aggressive hematological malignancy with outcomes influenced by various factors, including age, white blood cell count, and risk classification. Serum albumin, a critical component of blood, plays a role in maintaining colloid osmotic pressure and has been identified as a prognostic marker in various cancers, including AML.

At this year’s European Hematology Association (EHA) conference, we had the opportunity to speak with Dr. Swaminathan P iyer, Professor of Medicine at MD Anderson Cancer Center, about the groundbreaking phase I study on ELA26 for secondary hemophagocytic lymphohistiocytosis (HLH). Dr. Iyer shared the promising data from the treatment-naive cohort, which showed a remarkable 100% response rate by two months, offering new hope to patients dealing with this life-threatening complication. As HLH has a high mortality rate, with most patients unable to receive adequate malignancy treatment due to complications, this study opens new doors for future integration with chemotherapy.

From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the top international conferences in the oncology field, it brought together experts and scholars from around the world to share cutting-edge research findings and discuss future development directions. At this year's conference, a study led by Dr. Peng Liu's team from Zhongshan Hospital, Fudan University, was selected for a Mini Oral presentation, which was delivered on-site by Dr. Jiadai Xu. The study explored a chemotherapy-free first-line treatment approach for marginal zone lymphoma (MZL), with preliminary results proving promising. Hematology Frontier invited Dr. Xu for an in-depth discussion on the study and her expectations for the future of this treatment approach and research plans.

From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was grandly held, attracting global experts to foster academic exchange and cooperation. During the conference, Hematology Frontier invited Dr. Peiqi Zhao from Tianjin Medical University Cancer Institute and Hospital to discuss the latest advances in follicular lymphoma treatment and the evolving concept of comprehensive disease management.

From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was successfully held. The conference featured 12 specialized sessions, including immunotherapy, translational research, and new drug development, creating a platform that fosters international academic exchange and cooperation. During the event, Hematology Frontier had the privilege of interviewing the conference chair, Dr. Huilai Zhang from Tianjin Medical University Cancer Institute & Hospital. He shared insights into the highlights of the conference and the future development of lymphoma research.

Multiple Myeloma (MM) is a common hematologic malignancy, and with the emergence of immunotherapy, particularly CAR-T therapy as a revolutionary immunotherapeutic approach, the survival of patients with relapsed/refractory multiple myeloma (R/R MM) has significantly improved. From April 14th to 17th, 2024, the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Glasgow, United Kingdom, focusing on the latest advancements in stem cell transplantation and cell therapy, driving towards better clinical outcomes for hematologic disease patients. At this conference, Professor Chunrui Li from Tongji Hospital affiliated with Huazhong University of Science and Technology School of Medicine in China presented a study comparing the efficacy of five currently available BCMA-targeting CAR-T cell products, attracting widespread attention. In this exclusive interview, Professor Chunrui Li shares the main findings of the study and provides insightful interpretations of the latest research advancements in CAR-T cell therapy for R/R MM.